Predictive capacity of histamine release for the diagnosis of drug allergy

Abstract

The usefulness of the in vitro histamine-release test for the diagnosis of drug allergy appears to be insufficient.

Complement activation-related pseudoallergy: A stress reaction in blood triggered by nanomedicines and biologicals

“…This is in contrast with the clinical relevance of the phenomenon, considering the estimated high percentage (>77%) of non-IgE-mediated reactions among all hypersensitivity reactions (HSRs) to drugs (Demoly et al, 1999). These pseudoallergic reactions afflict, according to different statistics, up to 500 thousands patients every year in the USA (Lazarou et al, 1998;Adkinson et al, 2002).…”

Drug-Induced Pseudoallergy: A Review of the Causes and Mechanisms

“…It has been suggested that two-thirds of HSRs may be attributable to pseudoallergy [9]. Due to the lack of systematic studies of the causes and mechanisms involved in pseudoallergy, the diagnosis and treatment of these reactions remain a significant clinical challenge.…”

Factor H inhibits complement activation induced by liposomal and micellar drugs and the therapeutic antibody rituximab in vitro

“…application of certain nanoparticlecontaining medicines. [1][2][3] Premedication with steroids and other anti-allergic medicines can reduce the risk and severity of such adverse reactions; however, prevention by inhibiting the triggering mechanisms, e.g. complement activation, is expected to offer more specific and effective measure against this adverse immune effect.…”